Combining ATR suppression with oncogenic ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9693-9702

  Gilad, Oren ^a   Nabet, Barzin Y ^a   Ragland, Ryan L ^a   Schoppy, David W ^a   Smith, Kevin D ^a   Durham, Amy C ^b   Brown, Eric J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; HISTONE H2AX; K RAS PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CELL CYCLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CHROMOSOME DELETION; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; GENE REPRESSION; GENETIC ASSOCIATION; GENETIC TRANSFORMATION; GENOMIC INSTABILITY; HETEROZYGOSITY; LETHALITY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SISTER CHROMATID EXCHANGE; SPINDLE CELL SARCOMA; THYMUS LYMPHOMA; TUMOR PROMOTION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENOMIC INSTABILITY; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649929369     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2286     Document Type: Article

References (50)

1. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA 1994;91:5124-8.
2. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
3. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
4. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006;444:638-42.
5. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444: 633-7.
6. Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL. Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem 2006;281:34759-67. (Pubitemid 46043245)
7. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature 2007;448:445-51. (Pubitemid 47123512)
8. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319:1352-5. (Pubitemid 351354863)
9. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair (Amst) 2007;6:953-66.
10. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008;9:616-27. (Pubitemid 352032926)
11. Davidson IF, Li A, Blow JJ. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol Cell 2006;24:433-43. (Pubitemid 44647903)
12. Moiseeva O, Bourdeau V, Roux A, Deschenes-Simard X, Ferbeyre G. Mitochondrial dysfunction contributes to oncogene-induced senescence. Mol Cell Biol 2009;29:4495-507.
13. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000;14: 397-402. (Pubitemid 30131885)
14. Myung K, Datta A, Kolodner RD. Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell 2001;104:397-408. (Pubitemid 32206460)
15. Tercero JA,, Diffley JF. Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. Nature 2001;412:553-7.
16. Lopes M, Cotta-Ramusino C, Pellicioli A, Liberi G, Plevani P, Muzi- Falconi M, et al. The DNA replication checkpoint response stabilizes stalled replication forks. Nature 2001;412:557-61. (Pubitemid 32743836)
17. Cha RS, Kleckner N. ATR homolog Mec1 promotes fork progression, thus averting breaks in replication slow zones. Science 2002; 297:602-6. (Pubitemid 34815344)
18. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-89. (Pubitemid 36106400)
19. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003;17: 615-28. (Pubitemid 36307546)
20. Byun TS, Pacek M, Yee MC, Walter JC, Cimprich KA. Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev 2005;19:1040-52. (Pubitemid 40632450)
21. Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ, et al. ATR and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem 2009;284:5994-6003.
22. Smith KD, Fu MA, Brown EJ. Tim-Tipin dysfunction creates an indispensible reliance on the ATR-Chk1 pathway for continued DNA synthesis. J Cell Biol 2009;187:15-23.
23. Durkin SG, Arlt MF, Howlett NG, Glover TW. Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites. Oncogene 2006;25:4381-8.
24. Loo DT, Fuquay JI, Rawson CL, Barnes DW. Extended culture of mouse embryo cells without senescence: inhibition by serum. Science 1987;236:200-2.
25. Woo RA, Poon RY. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev 2004;18:1317-30.
26. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001;15:3243-8. (Pubitemid 34008190)
27. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-87.
28. Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cells 2007;1:113-26. (Pubitemid 46865802)
29. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004;64:2307-16.
30. Menoyo A, Alazzouzi H, Espin E, Armengol M, Yamamoto H, Schwartz S, Jr, et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001;61:7727-30. (Pubitemid 33049356)
31. Vassileva V, Millar A, Briollai L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002;62:4095-9. (Pubitemid 34791080)
32. Lewis KA, Mullany S, Thomas B, Chien J, Loewen R, Shridhar V, et al. Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res 2005;65: 7091-5. (Pubitemid 41161237)
33. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5.
34. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
35. Lewis KA, Bakkum-Gamez J, Loewen R, French AJ, Thibodeau SN, Cliby WA, et al. Mutations in the ataxia telangiectasia and rad3- related-checkpoint kinase 1 DNA damage response axis in colon cancers. Genes Chromosomes Cancer 2007;46:1061-8. (Pubitemid 47614540)
36. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-66.
37. Tanaka Y, Maniwa Y, Bermudez VP, Doi T, Nishio W, Ohbayashi C, et al. Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk. Cancer 2010;116:896-902.
38. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6. (Pubitemid 32391044)
39. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 2004;101:597-602. (Pubitemid 38084682)
40. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113:528-38. (Pubitemid 38542502)
41. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62. (Pubitemid 34008191)
42. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
43. Navadgi-Patil VM, Burgers PM. The unstructured C-terminal tail of the 9-1-1 clamp subunit Ddc1 activates Mec1/ATR via two distinct mechanisms. Mol Cell 2009;36:743-53.
44. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/ M DNA damage checkpoint. Genes Dev 2000;14:1448-59.
45. Fang Y, Tsao CC, Goodman BK., Furumai R, Tirado CA, Abraham RT, et al. ATR functions as a gene dosage-dependent tumor suppressor on a mismatch repair-deficient background. EMBO J 2004;23:3164-74. (Pubitemid 39093610)
46. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009;16:324-35.
47. Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, et al. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol 2009;27:3091-6.
48. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:216-25. (Pubitemid 38337501)
49. Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, et al. A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2010. [Epub ahead of print].
50. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005;25:3553-62. (Pubitemid 40559562)